Asthma and lower airway diseaseAeroallergen sensitization correlates with PC20 and exhaled nitric oxide in subjects with mild-to-moderate asthma
Section snippets
Methods
We assessed data from subjects who provided written informed consent and were randomized into multiple studies performed by the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network (ACRN). Subjects were recruited from pulmonary and allergy clinics and through advertisements to the general public. The vast majority of subjects were recruited from non–allergy clinic populations. The studies included SOCS,10 SLIC,11 BARGE,12 BAGS,13 CIMA,14 MICE,15 DICE,16 IMPACT,17 SMOG,18
Results
One thousand three hundred thirty-eight subjects were included in this analysis, and Table I summarizes their baseline characteristics. Additional demographics are available in Table II. Patients ranged in age from 12 to 65 years, with 58% being female and 42% being male. Ethnicity distribution included 65% white, 21% African American, 8% Hispanic, and 6% “other.” Skin test results to specific antigens and to positive and negative controls are noted in Table III.
Ninety-five percent of subjects
Discussion
Our data demonstrate that as many as 95% of subjects with mild-to-moderate asthma have aeroallergen sensitization. Unfortunately, we are unable to determine by using our database whether allergy symptoms and skin test results correlated. Ideally, the term “allergic” should be reserved for patients with symptoms associated with exposure to the allergen identified by a positive skin test response. Therefore for the purpose of this article and consistent with the literature, we have used the term
References (50)
- et al.
Association between atopic sensitization and asthma and bronchial hyperresponsiveness in Swedish adults: pets, and not mites, are the most important allergens
J Allergy Clin Immunol
(1999) - et al.
Comparison of patterns of allergen sensitization among inner-city Hispanic and African American children with asthma
Ann Allergy Asthma Immunol
(2006) - et al.
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial
Lancet
(2004) - et al.
Significant variability in response to inhaled corticosteroids for persistent asthma
J Allergy Clin Immunol
(2002) - et al.
The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial
J Allergy Clin Immunol
(2007) - et al.
High frequency of atopic asthma in a pulmonary clinic population
Chest
(1989) - et al.
Exposure to domestic animals and risk of immunologic sensitization in subjects with asthma
J Allergy Clin Immunol
(1993) - et al.
Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy
J Allergy Clin Immunol
(1996) - et al.
Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma
J Allergy Clin Immunol
(2004) - et al.
Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation
J Allergy Clin Immunol
(2004)
Atopy in subjects with asthma followed to the age of 28 years
J Allergy Clin Immunol
The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years
Respir Med
House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program
J Allergy Clin Immunol
Relationship of indoor allergen exposure to skin test sensitivity in inner-city children with asthma
J Allergy Clin Immunol
Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide
J Allergy Clin Immunol
Changes in bronchial responsiveness following nasal provocation with allergen
J Allergy Clin Immunol
Sociodemographic correlates of indoor allergen sensitivity among United States children
J Allergy Clin Immunol
The role of indoor allergens in chronic allergic disease
J Allergy Clin Immunol
A community-based study of the epidemiology of asthma. Incidence rates, 1964-83
Am Rev Respir Dis
Evaluation of the prevalence of skin prick positivity to Alternaria and Cladosporium in patients with suspected respiratory allergy. A European multicenter study promoted by the Subcommittee on Aerobiology and Environmental Aspects of Inhalant Allergens of the European Academy of Allergology and Clinical Immunology
Allergy
Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults
Allergy
RAST and skin test screening in the investigation of asthma
Ann Allergy
How exposures to biologics influence the induction and incidence of asthma
Environ Health Perspect
Asthma severity and atopy: how clear is the relationship
Arch Dis Child
High prevalence of skin test positivity in severe or difficult-to-treat asthma
J Asthma
Cited by (0)
Supported by grants U10-HL51831, U10-HL51845, U10-HL51823, U10-HL51843, U10-HL56443, U10-HL51834, U10-HL51810, U10-HL74227, U10-HL74231, U10-HL74204, U10-HL74212, U10-HL74073, U10-HL74206, U10-HL74208, U10-HL74225, and U10-HL74218.
Disclosure of potential conflict of interest: T. J. Craig is on the advisory board for Aventis; has consulting arrangements with Genentech/Novarits, Glaxo, Schering-Plough, and AstraZeneca; and has received research support from Schering-Plough, Merck, Glaxo, ACAAI, Methaparm, Dyax, Lev, PDL, Centacore, Sanofi-Aventis, and Altana. R. F. Lemanske has consulting arrangements with Novartis, Merck, GlaxoSmithKline, Aventis, and AstraZeneca; has received research support from the National Heart, Lung, and Blood Institute; and is on the speakers' bureau for Merck and GlaxoSmithKline. M. E. Weshsler has consulting arrangements with Genentech, Novartis, Merck, Aerocrine, Graceway, and Schering-Plough; has received research support from GlaxoSmithKline; an is on the speakers' bureau for Genentech, Novartis, Merck, and GlaxoSmithKline. S. Wasserman has consulting arrangements with AstraZeneca, Genentech, Novartis, Tanex, Icos, Vistakon, Tanabe, and Amylin; has received research support from GlaxoSmithKline, and Schering-Plough; is on the speakers' bureau for AstraZeneca; has served as an expert witness in medical malpractice cases about anaphylaxis, asthma, and drug allergies; and has served as an expert witness on the health effects of mold exposure. The rest of the authors have declared that they have no conflict of interest.